Imatinib (Gleevec®)-induced hepatotoxicity

Walid S. Ayoub, Stephen A. Geller, Tram Tran, Paul Martin, John M. Vierling, F. Fred Poordad

Research output: Contribution to journalArticle

46 Scopus citations


Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalJournal of clinical gastroenterology
Issue number1
StatePublished - Jan 1 2005



  • Gleevec®
  • Hepatotoxicity
  • Imatinib

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ayoub, W. S., Geller, S. A., Tran, T., Martin, P., Vierling, J. M., & Poordad, F. F. (2005). Imatinib (Gleevec®)-induced hepatotoxicity. Journal of clinical gastroenterology, 39(1), 75-77.